So why is Zavante brushing the dust off fosfomycin? After all, it was actually first tested in the 1960s in Spain, but had been ruled as fairly ineffective in comparison to other antibiotics on the market.
Zavante Therapeutics' antibiotic is scheduled to enter clinical trials next quarter, with aims to treat complicated urinary tract infections.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.